New drug aims to slow kidney disease in 3,000-Patient trial
NCT ID NCT06866236
First seen Nov 01, 2025 · Last updated Jun 23, 2026 · Updated 33 times
Summary
This study tests a new drug called QRX3 in 3,000 people with chronic kidney disease. The goal is to see if it can improve kidney function and slow the disease's progression. Participants will take QRX3 capsules, and researchers will measure changes in kidney function over time.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for KIDNEY FAILURE are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Neukidney Inc
Pasedena, Texas, 77504, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
QRX-3 (a drug that targets kidney function)
What this could lead to
If successful, this could provide a new treatment option to slow or prevent worsening of chronic kidney disease, potentially reducing the need for dialysis.
What could go wrong
This is an early phase 2/3 trial, so the drug may not work as hoped. Side effects are possible, and results may not apply to all kidney disease patients.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.